Venetoclax Plus Inotuzumab for B-ALL

NCT05016947 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

23

Enrollment

OTHER

Sponsor class

Conditions

B-cell Acute Lymphoblastic Leukemia
B-Cell Lymphoma
ALL

Interventions

DRUG: Venetoclax
DRUG: Dexamethasone
DRUG: Inotuzumab Ozogamicin

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]